Search clinical trials for: LDK378
Total 29 results
-
Novartis PharmaceuticalsCompletedNon-Small-Cell Lung CancerJapan
-
Novartis PharmaceuticalsCompletedTumors Characterized by Genetic Abnormalities of ALKAustralia, Belgium, Germany, Netherlands, Spain, Italy, Singapore, Korea, Republic of, United Kingdom, United States, Canada
-
Novartis PharmaceuticalsCompletedNon-Small Cell Lung CancerCanada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
-
Novartis PharmaceuticalsNo longer availableNon-small Cell Lung Cancer (NSCLC)United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
-
Anne Beaven, MDNovartisWithdrawnHematologic MalignanciesUnited States
-
Novartis PharmaceuticalsCompletedALK-activated TumorsFrance, Spain, Germany, Italy, Korea, Republic of, Canada, Australia, United Kingdom, Netherlands, United States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Novartis PharmaceuticalsCompletedNon-Small Cell Lung CancerUnited Kingdom, Taiwan, Belgium, Spain, Canada, Italy, Singapore, Japan, Russian Federation, Hong Kong, Thailand, Korea, Republic of, Norway, Australia, France, Sweden, United States, New Zealand
-
Novartis PharmaceuticalsAvailableNon-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
-
Novartis PharmaceuticalsCompletedNon-Small Cell Lung CancerCanada, Taiwan, United States, Italy, Korea, Republic of, Thailand, Belgium, Germany, Austria, Turkey, Greece, United Kingdom, Colombia, India, Malaysia, Brazil, Spain, Poland, Bulgaria, Australia, Czechia, Lebanon, Netherlands, Russian...
-
Novartis PharmaceuticalsCompletedNon-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)Australia, Spain, Singapore, Italy, United States
-
Novartis PharmaceuticalsTerminatedCeritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)Tumors With Aberrations in ALK or ROS1United States
-
Novartis PharmaceuticalsCompletedTumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)Japan
-
Novartis PharmaceuticalsTerminatedGlioblastoma | Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumor | Tumors With Aberrations in ALKFrance, Czechia, Italy, Spain, Korea, Republic of, Thailand, Israel, Denmark
-
Yonsei UniversityUnknownNon-small Cell Lung Cancer (NSCLC)Korea, Republic of
-
Novartis PharmaceuticalsCompletedALK-positive Non-small Cell Lung CancerUnited States, France, Italy, United Kingdom, Taiwan, Turkey, Belgium, Germany, Canada, Singapore, Spain, Korea, Republic of, Netherlands, Russian Federation, Brazil, Hong Kong, Australia
-
Yonsei UniversityUnknownNon-small Cell Lung Cancer Harboring ROS1 RearrangementKorea, Republic of
-
Novartis PharmaceuticalsCompletedNon-small Cell Lung CancerTaiwan, Spain, Italy, United States, Korea, Republic of, France
-
Novartis PharmaceuticalsCompletedAdenocarcinoma Lung Cancer; Squamous Cell Lung CarcinomaChina
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; National Cheng-Kung University HospitalTerminated
-
Novartis PharmaceuticalsActive, not recruitingALK-positive NSCLCBelgium, Spain, Italy, Australia, United States, Hong Kong, Canada, Singapore
-
Novartis PharmaceuticalsCompletedNon-Small Cell Lung CancerItaly, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
-
University of California, San FranciscoTerminatedALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK PositiveUnited States
-
Yael P MosseNovartis Pharmaceuticals; Foundation MedicineTerminated
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNovartisCompletedAdvanced Malignant Solid Neoplasm | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | ALK PositiveUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell CarcinomaUnited States